<?xml version="1.0" encoding="ISO-8859-1"?><!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78950</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125151855</messagedate>
</ichicsrmessageheader> 
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>US-SANOFI-AVENTIS-2013SA002985</safetyreportid>
<primarysourcecountry>US</primarysourcecountry>
<occurcountry>US</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20130125</transmissiondate>
<reporttype>1</reporttype>
<serious>1</serious>
<seriousnessdeath>2</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>1</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<seriousnessother>2</seriousnessother>
<receivedateformat>102</receivedateformat>
<receivedate>20130114</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>20130114</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>US-SANOFI-AVENTIS-2013SA002985</companynumb>
<primarysource>
<reportertitle>MS.</reportertitle>
<reportergivename>NANCY</reportergivename>
<reporterfamilyname>ENGERMANN</reporterfamilyname>
<reporterstreet>3002 ESSEX ROAD</reporterstreet>
<reportercity>KALAMAZOO</reportercity>
<reporterstate>MI</reporterstate>
<reportercountry>US</reportercountry>
<qualification>5</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>NE</patientinitial>
<patientbirthdateformat>102</patientbirthdateformat>
<patientbirthdate>19350407</patientbirthdate>
<patientonsetage>77</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>6</patientagegroup>
<patientsex>2</patientsex>
<reaction>
<primarysourcereaction>bowel obstruction</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10006055</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>610</reactionstartdateformat>
<reactionstartdate>201211</reactionstartdate>
<reactionenddateformat>610</reactionenddateformat>
<reactionenddate>201211</reactionenddate>
<reactionfirsttime>1</reactionfirsttime>
<reactionfirsttimeunit>801</reactionfirsttimeunit>
<reactionoutcome>1</reactionoutcome>
</reaction>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>MULTAQ</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 22-425</drugauthorizationnumb>
<drugstructuredosagenumb>400</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>2</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosageform>TABLET</drugdosageform>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10003658</drugindication>
<drugstartdateformat>610</drugstartdateformat>
<drugstartdate>201110</drugstartdate>
<drugstartperiod>1</drugstartperiod>
<drugstartperiodunit>801</drugstartperiodunit>
<actiondrug>6</actiondrug>
<activesubstance>
<activesubstancename>DRONEDARONE</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>Initial information was received from a consumer on 14-Jan-2013:

A 77 year-old female with an unknown medical history initiated dronedarone (Multaq) 400 mg twice daily with meals for atrial fibrillation in October 2011. In November 2012 she was in the hospital for 9 days with a bowel obstruction. For 5 days while in the hospital she was unable to eat and she was given dronedarone (Multaq) without food. Therapy with dronedarone continued. Concomitant medications were not provided. No further relevant was provided.</narrativeincludeclinical>
<sendercomment>Sanofi Company Comment dated 14-Jan-2013: a 77-year old female patient with an unknown medical history had developed a bowel obstruction while being treated with Multaq (dronedarone) for about one year for atrial fibrillation. Limited information provided precludes an assessment of the case. Additional information such as details of the reported event and hospitalization with the results of the diagnostics performed, concomitant medications and medical history is needed and will be requested.</sendercomment>
</summary>
</patient>
</safetyreport> 
</ichicsr>
